



Transform Grow

Investors & Analyst Communication on Financial Results **Q2 & H1 as on 30 September 2018**

Dated: 5 November 2018





Safe Harbour Statement

"This Presentation, except for the historical information, may contain statements, including the words or phrases such as 'expects, anticipates, intends, will, would, undertakes, aims, estimates, contemplates, seeks to, objective, goal, projects, should' and similar expressions or variations of these expressions or negatives of these terms indicating future performance or results, financial or otherwise of Tata Chemicals Limited, its direct and indirect subsidiaries and its associates. Actual results might differ substantially or materially from those expressed or implied. Important factors that could make a difference to the Company's operations include, among others, economic conditions affecting demand / supply, price conditions in the domestic and overseas markets in which the Company operates, changes in Government policies and regulations, tax laws, and other statutes and incidental factors. You are urged to view all statements contained herein with caution. Tata Chemicals Limited does not undertake any obligation to update or revise forward look statements, whether as a result of new information, future events or otherwise"







Board Approval on Capital Expenditure plan at Mithapur:

- The Company's Board of Directors approved capital expenditure of Rs 2,400 Cr, towards capacity expansion at Mithapur Facility
- Move to enhance Soda Ash capacity by about 150,000 MT, salt production by 400,000 MT and upgrade turbines for higher efficiency with a reduction in our carbon footprint
- This expansion will be achieved without any additional carbon generation by focusing from waste heat, solar and wind

Entry into Lithium –ion battery sector and energy storage application:

- Plan to enter into the Lithium-ion battery sector to develop cell chemistries to meet Indian application
- Expected market in India for these application could be 40-60 GWh by 2025






Key Summary Financial Highlights

- Q2 vs. PY Q2 PAT Continuing Consolidated Rs 409 Cr (↑ 17%, ↑ 59crs), Standalone Rs 295 Cr (↑ 109% ↑ 154 Cr)
- H1 vs. PY H2 PAT Continuing Consolidated Rs 678 Cr (↑ 16%, ↑ 92 Cr), Standalone Rs 559 Cr (↑ 89% ↑ 263 Cr)
- **Standalone** includes incremental FX Gains & Group Dividends Q2 Rs. 74 Cr, H1 Rs. 117 Cr, reversed on consolidation
- TCNA production Q2 565 KT (↓ 8%, 51 KT), H1 1,089 KT (↓ 7%, 85 KT)
- CPB Tata Salt vols. 255 KT (↑10%, 24 KT) 502KT (↑15% 66 KT)
- Consolidated Net Debt Rs 2,180 Cr (Rs 320 Cr), Cash & Equivalent Rs 4,441 Cr
- Standalone Net Cash Rs 2,474 Cr, Cash & Equivalent Rs 3,665 Cr





Financial Highlights for the Quarter ended 30 September 2018




Note: Financials are for Continuing Operations only Consolidated PAT is before Non-controlling Interest





Financial Highlights for Year Till Date 30 September 2018



Note: Financials are for Continuing Operations only, Discontinued Operation reported a net loss of Rs (8) Cr (PY Profit of Rs 75 Cr) Consolidated PAT is before Non-controlling Interest



Results





Reporting Segment – Q2


Consolidated

*Excludes Inter Segment Revenue of **Rs 207 Cr** (PY Rs. 182 Cr) & Unallocated Revenue of **Rs 7 Cr** (PY Rs 6 Cr)

* Sept 2017 Rs Cr * 2,866











Standalone

*Excludes Inter Segment Revenue of **Rs 200 Cr** (PY Rs. 180 Cr) & Unallocated Revenue of **Rs 4 Cr** (PY Rs 6 Cr)









Basic Chemistry Products

Consumer Products

Specialty Products






Balance Sheet as on 30 September 2018

Rs Cr	Consolidated		Standalone	
K3 01	31-Mar-18	30-Sep-18	31-Mar-18	30-Sep-18
<u>ASSETS</u>				
Non - Current Assets	16,839	18,339	8,484	8,865
Current Assets				
Inventories	1,462	1,485	451	487
Trade Receivables	1,308	1,673	140	192
Cash and Cash Equivalent (including Bank balance & Current Investments)	4,575	4,380	3,769	3,603
Others Current Assets	596	978	244	576
Assets Classified as held for Sale	1,098	13	1,086	-
Total Assets	25,879	26,869	14,174	13,723
EQUITY AND LIABILITIES				
Equity & Reserves	11,102	11,336	11,324	11,031
Non - Controlling Interests	2,717	3,000	-	-
Non-Current Liabilities				
Borrowings (Non Current)	5,394	5,594	681	476
Non-Current Liabilities	2,962	3,079	300	271
Current Liabilities				
Borrowings (Current)	140	139	1	3
Trade Payables	1,479	1,606	425	517
Others Current Liabilities	1,535	2,115	893	1,424
Liabilities associated with assets classified as held for Sale	550	-	550	-
Total Equities and Liabilities	25,879	26,869	14,174	13,723






Basic Chemistry Products









- India operations continue to register healthy volumes and margins due to improved operational efficiencies, despite higher energy prices
- North America operations witnessed strong demand. However performance was impacted due to lower operational efficiencies and the installation of new environmental equipment, partially offset by better sales realization
- TCEL performance was muted on account of lower trading activity and higher fixed costs.
- TCML performance back on track, with revenue improving due to higher sales realization. Margin's were subdued due to higher fixed cost and higher plant spent.






Consumer Products







- Consumer products business registered a growth of 22% over the Q2 FY18.
- TATA Salt continues to maintain its leadership position, with increased volumes and realization.
- Pulses & Spices portfolios revenue grew by ~130%, majorly contributed by higher sales volumes as compared to Q2 FY18.
- Improvement in market reach and availability remains our focus, especially in modern format stores and online retailing










Note: Consumer Products includes Salt, Pulses, Spice and other branded consumer products





Specialty Products







- Higher sales volumes from International business supported Rallis india 's performance.
- Sales in Nutritional solutions where higher due to improved sale volumes. Margins where impacted due to higher fixed costs.

100% NATURAL. 100% BIOEASY"

 Our new facilities, Nutraceuticals in Nellore & Silica in Cuddalore, are on schedule for commissioning in 2019.

Note: Specialty Products includes Nutritional Solutions, Advance Materials, Traded seeds, pesticides and specialty crop nutrients





Subsidiary Financials

Quarter ended September

Units	TCL India	
Rs Cr	PY	CY
Revenue	826	1,014
EBITDA	229	256
PBT	224	380
PAT	141	295

US		
PY	CY	
857	858	
218	170	
141	89	
69	45	

UK		
PY	CY	
355	353	
55	33	
18	6	
18	6	

Africa		
PY	CY	
115	128	
22	13	
12	4	
12	4	

Rallis		
PY	CY	
588	656	
122	126	
112	119	
77	85	

Consolidated*		
PY	CY	
2,690	2,961	
638	602	
438	492	
258	322	

YTD Sept 2018

Units	TCL India	
Rs Cr	PY	CY
Revenue	1,694	2,003
EBITDA	438	512
PBT	445	748
PAT	296	559

US		
PY	CY	
1,652	1,623	
367	302	
211	141	
96	66	

UK		
CY		
697		
64		
11		
11		

Africa		
PY	CY	
228	220	
42	(2)	
20	(21)	
20	(21)	

Rallis		
PY	CY	
1,049	1,227	
192	207	
174	195	
123	140	


Consolidated*	
PY	CY
5,218	5,705
1,116	1,093
778	865
431	536


- * Include SPV and after consolidation adjustments
- PBT is before exceptional items & Share of profit of Joint Ventures
- PAT (after NCI) for Equity Shareholders





Borrowings Position as on September 2018













Other Financial Information















For any question/queries please contact

Suraj Digawalekar

Suraj@cdr-india.com

№ +91 22 6645 1235

Registered Office: Bombay House, 24 Homi Mody Street, Fort, Mumbai, Maharashtra 400 001 India.

Tel: (022) 6665 8282 Fax: (022) 6665 8143 / 44